Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05337137 · ClinicalTrials.gov registry record · Phase 1

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

A Phase 1 study of Carcinoma, Hepatocellular, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
83
Enrollment target
20
Study locations

NCT05337137: Completed Phase 1 study of Carcinoma, Hepatocellular, sponsored by Bristol-Myers Squibb.

NCT05337137 is a Phase 1 study of Carcinoma, Hepatocellular that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 83 participants, below the 609-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05337137, a Phase 1 study of Carcinoma, Hepatocellular, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

Conditions Studied

Carcinoma, Hepatocellular

Interventions

  • DRUG Bevacizumab
  • OTHER Placebo
  • DRUG Nivolumab
  • DRUG Relatlimab

Study Locations (20)

California

  • Local Institution - 0042 - Los Angeles
  • Local Institution - 0039 - Los Angeles
  • Local Institution - 0034 - San Francisco

Massachusetts

  • Local Institution - 0060 - Boston
  • Local Institution - 0065 - Boston

New York

  • Local Institution - 0061 - New York
  • Local Institution - 0062 - The Bronx

Victoria

  • Local Institution - 0026 - Heidelberg
  • Local Institution - 0013 - Melbourne

District of Columbia

  • Local Institution - 0030 - Washington D.C.

Maryland

  • Local Institution - 0059 - Baltimore

Wisconsin

  • Local Institution - 0033 - Milwaukee

New South Wales

  • Local Institution - 0045 - Camperdown

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2022-05-05
Est. Completion 2025-11-18
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT05337137 record still lists

NCT05337137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 609-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT05337137 names 20 study sites across 15 states, led by California, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05337137 about?

NCT05337137 is a clinical study titled "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer". The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

What is the current status of trial NCT05337137?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2022-05-05. Estimated completion is 2025-11-18.

What conditions does trial NCT05337137 study?

This clinical trial studies the following conditions: Carcinoma, Hepatocellular.

What interventions are being tested in trial NCT05337137?

The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Nivolumab (DRUG), Relatlimab (DRUG).

Who is sponsoring clinical trial NCT05337137?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05337137 being conducted?

This trial has 20 study locations across California, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Hepatocellular

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05337137's enrollment target sits among peer trials

83 15th of 27 higher than 13 of 27 other Carcinoma, Hepatocellular trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05337137, the US trial registry maintained by the National Library of Medicine. NCT05337137 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.